Skip to main content
Journal cover image

Optimizing the Design of Clinical Trials to Evaluate the Efficacy of Function-Promoting Therapies.

Publication ,  Journal Article
Bhasin, S; Cawthon, PM; Correa-de-Araujo, R; Storer, TW; Volpi, E; Newman, AB; Dioh, W; Tourette, C; Evans, WJ; Fielding, RA
Published in: J Gerontol A Biol Sci Med Sci
June 16, 2023

BACKGROUND: Several candidate molecules that may have application in treating physical limitations associated with aging and chronic diseases are in development. Challenges in the framing of indications, eligibility criteria, and endpoints and the lack of regulatory guidance have hindered the development of function-promoting therapies. METHODS: Experts from academia, pharmaceutical industry, National Institutes of Health (NIH), and Food and Drug Administration (FDA) discussed optimization of trial design including the framing of indications, eligibility criteria, and endpoints. RESULTS: Mobility disability associated with aging and chronic diseases is an attractive indication because it is recognized by geriatricians as a common condition associated with adverse outcomes, and it can be ascertained reliably. Other conditions associated with functional limitation in older adults include hospitalization for acute illnesses, cancer cachexia, and fall injuries. Efforts are underway to harmonize definitions of sarcopenia and frailty. Eligibility criteria should reconcile the goals of selecting participants with the condition and ensuring generalizability and ease of recruitment. An accurate measure of muscle mass (eg, D3 creatine dilution) could be a good biomarker in early-phase trials. Performance-based and patient-reported measures of physical function are needed to demonstrate whether treatment improves how a person lives, functions, or feels. Multicomponent functional training that integrates training in balance, stability, strength, and functional tasks with cognitive and behavioral strategies may be needed to translate drug-induced muscle mass gains into functional improvements. CONCLUSIONS: Collaborations among academic investigators, NIH, FDA, pharmaceutical industry, patients, and professional societies are needed to conduct well-designed trials of function-promoting pharmacological agents with and without multicomponent functional training.

Duke Scholars

Published In

J Gerontol A Biol Sci Med Sci

DOI

EISSN

1758-535X

Publication Date

June 16, 2023

Volume

78

Issue

Suppl 1

Start / End Page

86 / 93

Location

United States

Related Subject Headings

  • Sarcopenia
  • Neoplasms
  • Humans
  • Gerontology
  • Frailty
  • Clinical Trials as Topic
  • Aging
  • Aged
  • 42 Health sciences
  • 32 Biomedical and clinical sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Bhasin, S., Cawthon, P. M., Correa-de-Araujo, R., Storer, T. W., Volpi, E., Newman, A. B., … Fielding, R. A. (2023). Optimizing the Design of Clinical Trials to Evaluate the Efficacy of Function-Promoting Therapies. J Gerontol A Biol Sci Med Sci, 78(Suppl 1), 86–93. https://doi.org/10.1093/gerona/glad024
Bhasin, Shalender, Peggy M. Cawthon, Rosaly Correa-de-Araujo, Thomas W. Storer, Elena Volpi, Anne B. Newman, Waly Dioh, Cendrine Tourette, William J. Evans, and Roger A. Fielding. “Optimizing the Design of Clinical Trials to Evaluate the Efficacy of Function-Promoting Therapies.J Gerontol A Biol Sci Med Sci 78, no. Suppl 1 (June 16, 2023): 86–93. https://doi.org/10.1093/gerona/glad024.
Bhasin S, Cawthon PM, Correa-de-Araujo R, Storer TW, Volpi E, Newman AB, et al. Optimizing the Design of Clinical Trials to Evaluate the Efficacy of Function-Promoting Therapies. J Gerontol A Biol Sci Med Sci. 2023 Jun 16;78(Suppl 1):86–93.
Bhasin, Shalender, et al. “Optimizing the Design of Clinical Trials to Evaluate the Efficacy of Function-Promoting Therapies.J Gerontol A Biol Sci Med Sci, vol. 78, no. Suppl 1, June 2023, pp. 86–93. Pubmed, doi:10.1093/gerona/glad024.
Bhasin S, Cawthon PM, Correa-de-Araujo R, Storer TW, Volpi E, Newman AB, Dioh W, Tourette C, Evans WJ, Fielding RA. Optimizing the Design of Clinical Trials to Evaluate the Efficacy of Function-Promoting Therapies. J Gerontol A Biol Sci Med Sci. 2023 Jun 16;78(Suppl 1):86–93.
Journal cover image

Published In

J Gerontol A Biol Sci Med Sci

DOI

EISSN

1758-535X

Publication Date

June 16, 2023

Volume

78

Issue

Suppl 1

Start / End Page

86 / 93

Location

United States

Related Subject Headings

  • Sarcopenia
  • Neoplasms
  • Humans
  • Gerontology
  • Frailty
  • Clinical Trials as Topic
  • Aging
  • Aged
  • 42 Health sciences
  • 32 Biomedical and clinical sciences